* Treace Medical Concepts Inc TMCI.OQ TMCI.O is expected
to report results on March 3.
* The Ponte Vedra Florida-based company is expected to
report
revenue of $32.267 million, according to the mean estimate from
3 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Treace Medical
Concepts
Inc is for breakeven results per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Treace
Medical
Concepts Inc is $33.5, about 35.7% above its last closing
price of $21.54.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.12 -0.12 -0.12 Met 0
Jun. 30 2021 -0.12 -0.12 -0.10 Beat 16.7
Mar. 31 2021 -0.06 -0.06 -0.07 Missed -16.7
This summary was machine generated March 1 at 22:37 GMT. All
figures in US dollars unless otherwise stated